Literature DB >> 28676302

Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.

Donald F Smee1, Mark N Prichard2.   

Abstract

Cell culture antiviral experiments were conducted in order to understand the relationship between percentage data generated by plaque reduction (PR) and logarithmic data derived by virus yield reduction (VYR) assays, using three-dimensional MacSynergy II software. The relationship between percentage and logarithmic data has not been investigated previously. Interpretation of drug-drug interactions is based on a Volume of Synergy (VS) calculation, which can be positive (synergy), negative (antagonistic), or neutral (no or minimal interaction). Interactions of two known inhibitors of vaccinia virus replication, cidofovir and 6-azauridine, used in combination by PR assay yielded a VS value of 265, indicative of strong synergy. By VYR, the VS value was only 37, or weak synergy using the same criterion, even though profound log10 reductions in virus titer occurred at multiple drug combinations. These results confirm that the differences in VS values is dependent of the measurement scale, and not that the degree of synergy differed between the assays. We propose that for logarithmic data, the calculated VS values will be lower for significant synergy and antagonism and that volumes of >10 μM2log10 PFU/ml (or other units such as μM2log10 genomic equivalents/ml or μM2log10 copies/ml) and <-10 μM2log10 PFU/ml are likely to be indicative of strong synergy and strong antagonism, respectively. Data presented here show that the interaction of cidofovir and 6-azauridine was strongly synergistic in vitro.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6-Azauridine; Cidofovir; Drug combination; Synergy; Vaccinia

Mesh:

Substances:

Year:  2017        PMID: 28676302      PMCID: PMC5575975          DOI: 10.1016/j.antiviral.2017.06.022

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  27 in total

1.  Orotidylic acid decarboxylase: inhibition studies with azauridine 5'-phosphate.

Authors:  R E HANDSCHUMACHER
Journal:  J Biol Chem       Date:  1960-10       Impact factor: 5.157

2.  The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme.

Authors:  Isabelle Bougie; Martin Bisaillon
Journal:  J Biol Chem       Date:  2004-03-22       Impact factor: 5.157

Review 3.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

4.  Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro.

Authors:  D F Smee; M Bray; J W Huggins
Journal:  Antivir Chem Chemother       Date:  2001-11

5.  CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.

Authors:  Mark N Prichard; Earl R Kern; Caroll B Hartline; E Randall Lanier; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

6.  Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.

Authors:  Donald F Smee; Brett L Hurst; Min-Hui Wong; Kevin W Bailey; E Bart Tarbet; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

7.  Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

Authors:  Natalia A Ilyushina; Erich Hoffmann; Rachelle Salomon; Robert G Webster; Elena A Govorkova
Journal:  Antivir Ther       Date:  2007

8.  Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines.

Authors:  E De Clercq; T Sakuma; M Baba; R Pauwels; J Balzarini; I Rosenberg; A Holý
Journal:  Antiviral Res       Date:  1987-12       Impact factor: 5.970

9.  Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.

Authors:  Natalia A Ilyushina; Alan Hay; Neziha Yilmaz; Adrianus C M Boon; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

10.  Development of ST-246® for Treatment of Poxvirus Infections.

Authors:  Robert Jordan; Janet M Leeds; Shanthakumar Tyavanagimatt; Dennis E Hruby
Journal:  Viruses       Date:  2010-11-03       Impact factor: 5.818

View more
  3 in total

1.  Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.

Authors:  Surabhi Talele; Wenjuan Zhang; Danielle M Burgenske; Minjee Kim; Afroz S Mohammad; Sonja Dragojevic; Shiv K Gupta; Ranjit S Bindra; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2021-09-23       Impact factor: 4.402

2.  Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.

Authors:  Sunwen Chou; Ronald J Ercolani; Katayoun Derakhchan
Journal:  Antiviral Res       Date:  2018-07-21       Impact factor: 5.970

3.  Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies.

Authors:  Ruben Soto-Acosta; Tiffany C Edwards; Christine D Dreis; Venkatramana D Krishna; Maxim C-J Cheeran; Li Qiu; Jiashu Xie; Laurent F Bonnac; Robert J Geraghty
Journal:  Viruses       Date:  2021-12-14       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.